An interventional study of biodex training in Hemolysis, sponsored by Ahram Canadian University. Recruiting at 1 site in Egypt. Open to female participants aged 35 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-01-25.
Sponsored by Ahram Canadian University · Not applicable, Interventional, and Treatment
imbalance is a common problem in hemodialysis patients with osteopneia, biodex training is a good device that treat imbalance
58 women with osteopenia problem and dialysis will be divided to trained women group with a number of 29 women receiving 3-time biodex training per week, every time will be 10 minutes for 12 weeks or nontrained women group that will act as a control group (n = 29 women)
Exclusion Criteria:
women group with a number of 29 women receiving 3-time biodex training per week, every time will be 10 minutes for 12 weeks
Behavioral: biodex training
this group will serve as a control group that will receive no intervention
women group with a number of 29 women receiving 3-time biodex training per week, every time will be 10 minutes for 12 weeks
bone mineral density of femur bone
it will be measured by DEXA
Time frame: it will be measured after 12 weeks
overall stability index
it a parameter indicates the good balance of patients
Time frame: it will be measured after 12 weeks
Antero posterior stability index
it a parameter indicates the good balance of patients
Time frame: it will be measured after 12 weeks
Mediolateral stability index
it a parameter indicates the good balance of patients
Time frame: it will be measured after 12 weeks
six minute walk test
it a parameter asses funntional capacity
Time frame: it will be measured after 12 weeks
Short physical performance battery
total score or points will be assessed from this physical performance test
Time frame: it will be measured after 12 weeks
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ahram Canadian University